Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Oct 1, 2026 → Oct 1, 2028
See other at-risk trials from National Cancer Institute (NCI)

Record History

The 50 most recent of 240 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Oct 1, 2026 to Oct 1, 2028
    • Study completion pushed from Nov 30, 2027 to Nov 30, 2032
  2. Minor Re-verified, no change to tracked fields
  3. Minor Eligibility criteria shortened, about 26 words
    • Study description expanded, about 11 words
  4. Minor 27 versions Re-verified since Jun 29, 2023, no change to tracked fieldsv211-v237
  5. Minor Study description revisedv210
Show 19 earlier versionsHide 19 earlier versions
  1. Minor 5 versions Re-verified since Dec 21, 2022, no change to tracked fieldsv205-v209
  2. Notable Primary completion date: Oct 1, 2025 to Oct 1, 2026
    • Study completion date: Nov 30, 2026 to Nov 30, 2027
    v204
  3. Minor Enrollment target: 56 to 66v203
  4. Notable Trial status: Suspended to Recruiting
    • Enrollment target: 10 to 56
    v202
  5. Minor Study Identification, Study Status, Study Description, Arms and Interventions, Outcome Measures, Eligibility, IPDSharingv201
  6. Minor 10 versions Re-verified since Jun 22, 2022, no change to tracked fieldsv191-v200
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective: To see if stem cell transplant can be successfully performed in people with primary immunodeficiency disease and cure them. Eligibility: People ages 4-69 for whom a primary immunodeficiency (PID) or Primary Immune Regulatory Disorder (PIRD), has caused significant health problems and either standard management has not worked or there are no standard management options, along with their donors Design: Donors will be screened under protocol 01-C-0129. They will donate blood or bone marrow. Participants will be screened with: Medical history Physical exam Blood, urine, and heart tests CT or PET scans Before transplant, participants will have dental and eye exams. They will have a bone marrow biopsy. For this, a needle will be inserted through the skin into the pelvis to remove marrow. Participants will be hospitalized before their transplant. They will have a central catheter put into a vein in their chest or neck. They will get medications through the catheter to prevent complications. Participants will get stem cells through the catheter. They will stay in the hospital for at least 4 weeks. They will give blood, urine, bone marrow, and stool samples. They may need blood transfusions. They may need more scans. They will take more medications. Participants will have visits on days 30, 60, 100, 180, and 360, and 24 months after the transplant. Then they will have visits once a year for about 5 years
Trial Details
NCT Number NCT04339777
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases, Common Variable Immunodeficiency, Primary T-cell Immunodeficiency Disorders
Related terms Autoimmune Diseases, Common Variable Immunodeficiency, Immune System Diseases, Lymphoproliferative Disorders, Opportunistic Infections, T cell immunodeficiency primary
Enrollment 66 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov